Hill-Rom Holdings Inc (HRC) Price Target Raised to $90.00

Hill-Rom Holdings Inc (NYSE:HRC) had its price target boosted by stock analysts at Barclays PLC from $86.00 to $90.00 in a research note issued on Monday. The brokerage presently has an “overweight” rating on the medical technology company’s stock. Barclays PLC’s target price indicates a potential upside of 14.69% from the company’s current price.

Several other research analysts also recently weighed in on HRC. Zacks Investment Research downgraded Hill-Rom Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub downgraded Hill-Rom Holdings from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Needham & Company LLC cut their price target on Hill-Rom Holdings from $95.00 to $93.00 and set a “buy” rating for the company in a research note on Friday, July 28th. Cantor Fitzgerald set a $86.00 price target on Hill-Rom Holdings and gave the stock a “hold” rating in a research note on Friday, July 28th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $84.00 price target on shares of Hill-Rom Holdings in a research note on Sunday, July 30th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $88.57.

Shares of Hill-Rom Holdings (NYSE HRC) traded up $0.97 during trading on Monday, hitting $78.47. The stock had a trading volume of 502,591 shares, compared to its average volume of 485,651. The stock has a market capitalization of $5,104.44, a PE ratio of 20.07, a price-to-earnings-growth ratio of 1.61 and a beta of 1.19. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55.

Hill-Rom Holdings (NYSE:HRC) last announced its earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.05. Hill-Rom Holdings had a return on equity of 20.27% and a net margin of 4.87%. The firm had revenue of $738.30 million during the quarter, compared to analyst estimates of $731.10 million. During the same period last year, the firm posted $1.18 EPS. The business’s revenue was up 4.6% compared to the same quarter last year. sell-side analysts expect that Hill-Rom Holdings will post 4.26 earnings per share for the current fiscal year.

WARNING: This report was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.com-unik.info/2017/11/06/hill-rom-holdings-inc-hrc-price-target-raised-to-90-00.html.

In other Hill-Rom Holdings news, SVP Andreas G. Frank sold 3,940 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $77.84, for a total value of $306,689.60. Following the completion of the transaction, the senior vice president now owns 16,701 shares in the company, valued at approximately $1,300,005.84. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Andreas G. Frank sold 6,870 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $77.48, for a total value of $532,287.60. Following the completion of the transaction, the senior vice president now owns 16,701 shares of the company’s stock, valued at approximately $1,293,993.48. The disclosure for this sale can be found here. 2.20% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its stake in Hill-Rom Holdings by 3.1% in the 2nd quarter. BlackRock Inc. now owns 5,226,138 shares of the medical technology company’s stock worth $416,053,000 after purchasing an additional 159,074 shares during the period. State Street Corp boosted its stake in Hill-Rom Holdings by 2.7% in the 2nd quarter. State Street Corp now owns 1,681,107 shares of the medical technology company’s stock worth $133,831,000 after purchasing an additional 43,645 shares during the period. Bank of New York Mellon Corp boosted its stake in Hill-Rom Holdings by 53.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,235,608 shares of the medical technology company’s stock worth $98,367,000 after purchasing an additional 427,888 shares during the period. Koch Industries Inc. bought a new position in Hill-Rom Holdings in the 2nd quarter worth about $1,007,000. Finally, Bank of Montreal Can boosted its stake in Hill-Rom Holdings by 2.1% in the 2nd quarter. Bank of Montreal Can now owns 1,007,525 shares of the medical technology company’s stock worth $80,206,000 after purchasing an additional 20,495 shares during the period. Institutional investors and hedge funds own 81.92% of the company’s stock.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom Holdings (NYSE:HRC)

What are top analysts saying about Hill-Rom Holdings Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hill-Rom Holdings Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit